Oncolytics Biotech Inc. (ONC.TO)
| Previous Close | 1.3300 |
| Open | 1.3500 |
| Bid | 1.3100 x 0 |
| Ask | 1.3200 x 0 |
| Day's Range | 1.2500 - 1.3600 |
| 52 Week Range | 1.2000 - 3.1800 |
| Volume | |
| Avg. Volume | 31,793 |
| Market Cap | 99.914M |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3800 |
| Earnings Date | Nov 01, 2024 - Nov 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.65 |
- Baystreet
Stocks in play: Oncolytics Biotech Inc
Announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C. Wainwright ...
PR NewswireOncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Chief Financial Officer Kirk Look will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference, which is taking place September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. Chief Medical Officer Tom Heineman, M.D., Ph.D., will participate in a fireside chat at the 2024 Cantor Global Healthcar
GlobeNewswireSernova Corp. Announces Appointment of New Chief Executive Officer
LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company’s new Chief Executive Officer. James Parsons, on behalf of the Board of Dir
